HTD1801,一种新的糖尿病药物,大大降低了血糖,改善了2型糖尿病试验病人的肾功能。 HTD1801, a new diabetes drug, significantly lowered blood sugar and improved kidney function in trial patients with type 2 diabetes.

在EASD会议上,HighTide Therapeutics宣布了SYMPHONY 2试验的积极的第三期结果,显示HTD1801,一种类别首创的抗炎代谢调节剂,与安慰剂相比,在2型糖尿病患者中显著降低了HbA1c水平. HighTide Therapeutics announced positive Phase 3 results from the SYMPHONY 2 trial at the EASD meeting, showing HTD1801, a first-in-class anti-inflammatory metabolic modulator, significantly reduced HbA1c levels in type 2 diabetes patients compared to placebo. 这种疗法激活了AMPK,抑制了NLRP3的炎症,还改进了葡萄糖控制、肾功能和炎症标记,具有有利的安全特征,没有严重的低血糖。 The therapy, which activates AMPK and inhibits the NLRP3 inflammasome, also improved glucose control, renal function, and inflammatory markers, with a favorable safety profile and no severe hypoglycemia. 调查结果表明,HTD1801可以作为心血管-幼儿-代谢疾病的综合治疗。 The findings suggest HTD1801 may serve as a comprehensive treatment for cardiovascular-kidney-metabolic disease.